Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Cheng

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Journal of Virology|October 31, 2006
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infectionSilvana Gaudieri, Andri Rauch, Lawrence P Park, et al.
Advances in Therapy|November 9, 2022
Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database StudyIain A Gillespie, K Arnold Chan, Yunhao Liu, et al.
The Lancet. Gastroenterology & Hepatology|November 13, 2019
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trialMan-Fung Yuen, Kosh Agarwal, Edward J Gane, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Drug and Alcohol Review|August 2, 2024
Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C)Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
Alimentary Pharmacology & Therapeutics|June 19, 2025
Surviving Hepatitis C-Understanding Death and Survival Beyond CurePaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Hepatology (Baltimore, Md.)|March 6, 2009
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapySilvana Gaudieri, Andri Rauch, Katja Pfafferott, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
Alimentary Pharmacology & Therapeutics|April 12, 2019
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levelsAmanda J Nicoll, Stuart K Roberts, Ricky Lim, et al.
Hepatology (Baltimore, Md.)|August 12, 2009
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressureAndri Rauch, Ian James, Katja Pfafferott, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Journal of Virology|October 31, 2006
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infectionSilvana Gaudieri, Andri Rauch, Lawrence P Park, et al.
Advances in Therapy|November 9, 2022
Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database StudyIain A Gillespie, K Arnold Chan, Yunhao Liu, et al.
The Lancet. Gastroenterology & Hepatology|November 13, 2019
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trialMan-Fung Yuen, Kosh Agarwal, Edward J Gane, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Drug and Alcohol Review|August 2, 2024
Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C)Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
Alimentary Pharmacology & Therapeutics|June 19, 2025
Surviving Hepatitis C-Understanding Death and Survival Beyond CurePaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Hepatology (Baltimore, Md.)|March 6, 2009
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapySilvana Gaudieri, Andri Rauch, Katja Pfafferott, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
Alimentary Pharmacology & Therapeutics|April 12, 2019
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levelsAmanda J Nicoll, Stuart K Roberts, Ricky Lim, et al.
Hepatology (Baltimore, Md.)|August 12, 2009
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressureAndri Rauch, Ian James, Katja Pfafferott, et al.
Pageof 7